1. Guideline on good pharmacovigilance practices (GVP). Module IX—Signal management (Rev 1). European Medicines Agency; 2017. https://www.ema.europa.eu/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-ix-signal-management-rev-1_en.pdf. Accessed 18 Apr 2018.
2. Agbabiaka TB, Savović J, Ernst E. Methods for causality assessment of adverse drug reactions: a systematic review. Drug Saf. 2008;31:21–37.
3. Théophile H, André M, Miremont-Salamé G, Arimone Y, Bégaud B. Comparison of three methods (an updated logistic probabilistic method, the Naranjo and Liverpool algorithms) for the evaluation of routine pharmacovigilance case reports using consensual expert judgement as reference. Drug Saf. 2013;36:1033–44.
4. Bégaud B, Evreux J, Jouglard J, Lagier G. Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France. Therapie. 1985;40:111–8.
5. France. Ministère des solidarités, de la santé et de la famille. Arrêté du 28 avril 2005 relatif aux bonnes pratiques de pharmacovigilance. JORF n°121 du 26 mai 2005, p. 9087. https://www.legifrance.gouv.fr/affichTexte.do?cidTexte=JORFTEXT000000812853. Accessed 16 Apr 2018.